H. Henry Dong, PhD
Associate Professor of Pediatrics
Dr. Dong is a member of the Cellular and Molecular Pathology Graduate Training Program.
Children's Hospital of Pittsburgh of UPMC
Rangos Research Center
4401 Penn Avenue
Pittsburgh, PA 15244
Office Telephone: 412-692-6324
Lab Telephone: 412-692-6570
- PhD - Uppsala University, Sweden, 1995
Awards and Honors
- 2006-2011 American Diabetes Career Development Award
- 2004-2006 American Diabetes Association Islet Cell Replacement Research Award
Research InterestsDr. Dong is an associate professor in the Department of Pediatrics, University of Pittsburgh School of Medicine. Dr. Dong focuses on studies of the molecular basis that links insulin resistance to diabetic dyslipidemia in subjects with morbid obesity and type 2 diabetes. Insulin resistance is defined as a significantly diminished state of responsiveness of the body to normal plasma insulin concentrations. To overcome insulin resistance in peripheral tissue, the pancreatic beta cells are called upon to produce more insulin via a compensatory mechanism, which over time can lead to beta-cell failure and overt diabetes. Despite tremendous efforts to elucidate the molecular basis of insulin resistance, a unifying idea to account for the pathophysiology of insulin resistance in obesity and type 2 diabetes is still lacking. Using transgenic, gene knockout and gene transfer approaches, Dr. Dong's lab focuses on the characterization of forkhead transcription factors in glucose and lipid metabolism to understand how insulin resistance perturbs carbohydrate metabolism, contributing to the development of diabetic dyslipidemia. These studies are expected to gain insight into the molecular events that link insulin resistance to metabolic abnormalities, providing a knowledge base for the development of small molecule drugs for better clinical management of diabetic dyslipidemia in obesity and type 2 diabetes.
Selected PublicationsView Dr. Dong's publications on PubMed
Kim DH, Zhang T, Lee S, Calabuig-Navarro V, Yamauchi J, Piccirillo A, Fan Y, Uppala R, Goetzman E, Dong HH. FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver. Endocrinology. 2014 155:1255-67. PMID: 24437489
Xiao G, Zhang T, Yu S, Lee S, Calabuig-Navarro V, Yamauchi J, Ringquist S, Dong HH. ATF4 deficiency protects against high fructose-induced hypertriglyceridemia in mice. J Biol Chem. 2013 288:25350-61. PMID: 23888053
Cifarelli V, Lee S, Kim DH, Zhang T, Kamagate A, Slusher S, Bertera S, Luppi P, Trucco M, Dong HH. FOXO1 Mediates the Autocrine Effect of Endothelin-1 on Endothelial Cell Survival. Mol Endocrinol. 2012 26:1213-24. PMID: 22570335.
Kim DH, Perdomo G, Zhang T, Slusher S, Lee S, Phillip BE, Fan Y, Giannoukakis N, Gramignoli R, Strom S, Ringquist S, Dong HH. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes. 2011 60:2763-2774. PMID: 21940782.
Kamagate A, Kim DH, Zhang T, Slusher S, Gramignoli R, Strom SC, Bertera S, Ringquist S, Dong HH. FoxO1 links hepatic insulin action to endoplasmic reticulum stress. Endocrinology 2010 151:3521-35. PMID: 20501674.
Su D, Coudriet GM, Kim DH, Lu Y, Perdomo G, Qu S, Slusher S, Tse HM, Piganelli J, Giannoukakis N, Zhang J and Dong HH. FoxO1 Links Insulin Resistance to Proinflammatory Cytokine IL-1beta Production in Macrophages. Diabetes. 2009 58:2624-2633. PMID: 19651810.
Kamagate A., Qu S., Perdomo G., Kim DH., Slusher S. Meseck, M and Dong HH. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production. J. Clin. Invest. 118:2347-2364. 2008. PMID: 18497885.
Altomonte, J., Cong, L., Richter, A., Harbaran, S., Xu, J., Nakae, J., Meseck, M., and Dong HH. (2004). FoxO1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 114:1493-1503. PMID: 15546000.